Thursday 27th May 2021
|Text too small?|
Fisher & Paykel Healthcare Corporation Limited today announced its results for the full year ended 31 March 2021. Operating revenue was $1.97 billion, up 56% or 61% in constant currency. Net profit after tax was $524 million, up 82% over the previous financial year, or 94% in constant currency.
Managing Director and CEO Lewis Gradon said, “It has been an extraordinary year and we want to thank healthcare professionals for giving their all to care for patients, often under the most difficult conditions. We also want to acknowledge the people of Fisher & Paykel Healthcare for their commitment to delivering for our customers, and the partners and families of our employees for the invaluable contribution they have made.
“To recognise the incredible contributions of our people, the Board has approved a profit-sharing bonus totalling $29 million for the 2021 financial year to be paid to everyone who has worked with us for a qualifying period. The company has also committed $20 million to establish the Fisher & Paykel Healthcare Foundation during the 2021 financial year. The Foundation’s charitable purposes include supporting and funding health research and programmes that improve access to healthcare, supporting environmental protection initiatives and promoting awareness of opportunities in science, technology, engineering and mathematics. The value of our total donations for the year, including product donations, was $26 million,” said Gradon.
The company’s directors have approved a final dividend of 22.0 cents per share, an increase of 42% on the final dividend last year. This brings the total dividend for the year to 38.0 cents per share, an increase of 38%. The final dividend, carrying full New Zealand imputation credit, will be paid on 7 July 2021 with a record date of 25 June 2021.
No guidance provided for the 2022 financial year
With the ongoing uncertainties of vaccinations, lockdowns, COVID-19 variants, localised waves and return to stable hospitalisation rates around the world, the company is not providing guidance for the 2022 financial year.
“We expect our Hospital and Homecare revenue for FY22 to be impacted by the number of COVID-19 related hospitalisations around the world,” said Gradon.
Please see the links below for details
No comments yet
Pacific Edge Limited (NZX: PEB) Placement Upsized Following Strong Demand
24th September 2021 Morning Report
23rd September 2021 Morning Report
Pacific Edge Limited (NZX: PEB) Dual Lists on ASX; Announces Capital Raise to Accelerate
Tower Limited (NZX: TWR) Updates Guidance
South Port New Zealand Limited (NZX: SPN) 2021 Annual Report
22nd September 2021 Morning Report
Kathmandu Holdings Limited (NZX: KMD) FY21 Annual Results Announcement
Stride Property Ltd & Stride Investment Management Ltd (NZX: SPG) Update on Demerger and Office Fund
21st September 2021 Morning Report